Home › Funds › BEACON INVESTMENT ADVISORY SERVICES, INC. › VRTX

BEACON INVESTMENT ADVISORY SERVICES, INC. position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

BEACON INVESTMENT ADVISORY SERVICES, INC. reported holding 47,986 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$25.1M, representing 0.95% of its reported portfolio and ranking #32 among its reported holdings. BEACON INVESTMENT ADVISORY SERVICES, INC. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)47.99K sh
Reported value held$25.09M
Portfolio Weight0.95%
First reportedQ3 2023
Last changeReduce
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How BEACON INVESTMENT ADVISORY SERVICES, INC.'s VRTX position evolved

BEACON INVESTMENT ADVISORY SERVICES, INC. first disclosed a stake in VRTX in Q3 2023 at 76,241 shares (US$26.5M). The position peaked in Q1 2025 at 77,901 shares, worth US$37.8M. Across 13 filings, BEACON INVESTMENT ADVISORY SERVICES, INC. increased the stake 2 time(s), trimmed it 7 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 47,986 shares valued at US$25.1M — a reduction of -5,394 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 76.24K $26.51M New
Q4 2023 77.92K $31.70M Add
Q1 2024 77.72K $32.49M Hold
Q2 2024 79.23K $37.14M Add
Q3 2024 79.17K $36.82M Hold
Q4 2024 78.82K $31.74M Hold
Q1 2025 77.90K $37.77M Reduce
Q2 2025 77.03K $34.29M Reduce
Q3 2025 76.14K $29.82M Reduce
Q4 2025 74.09K $33.59M Reduce
Q1 2026 56.10K $25.05M Reduce
Q2 2026 53.38K $26.52M Reduce
Q3 2026 47.99K $25.09M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has BEACON INVESTMENT ADVISORY SERVICES, INC. held VRTX?

BEACON INVESTMENT ADVISORY SERVICES, INC. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is BEACON INVESTMENT ADVISORY SERVICES, INC.'s current position in VRTX?

As of Q3 2026, BEACON INVESTMENT ADVISORY SERVICES, INC. holds 47.99K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $25.09M, representing 0.95% of its reported portfolio and ranking #32.

Has BEACON INVESTMENT ADVISORY SERVICES, INC. been buying or selling VRTX?

In the latest 13F filing (Q3 2026), BEACON INVESTMENT ADVISORY SERVICES, INC. reduced its position in VRTX. The position peaked in Q1 2025 at 77.90K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.